Related Experiment Videos
Post-OKT3 induction therapy CD complex response predicts renal allograft rejection
R N Stephan1, C E Munschauer, R K Kohli
1Department of Nephrology, State University of New York at Buffalo School of Medicine and Biomedical Sciences and The Buffalo General Hospital, 14203, USA.
Transplantation
|April 27, 1997
Summary
Monitoring CD complex repopulation after stopping OKT3 immunosuppression can predict kidney transplant rejection. Fast CD complex recovery indicates higher rejection risk, while slow recovery suggests better outcomes.
Area of Science:
- Immunology
- Transplantation
- Nephrology
Background:
- Immunosuppression is crucial for renal allograft survival.
- OKT3 (muromonab-CD3) is an immunosuppressive antibody used for induction therapy.
- Monitoring immune cell recovery post-immunosuppression is essential for personalized treatment.
Purpose of the Study:
- To investigate the correlation between CD complex repopulation after OKT3 cessation and subsequent renal allograft rejection.
- To determine if CD complex response patterns can predict graft outcomes.
Main Methods:
- Retrospective analysis of 27 renal allograft recipients treated with OKT3 induction.
- Flow cytometry was used to monitor CD complex (CD2, CD3, CD8) repopulation.
- Patients were categorized into fast responders, slow responders, and non-responders based on CD complex recovery levels.
Main Results:
- Fast responders (n=9) experienced graft loss or rejection episodes.
- Slow responders (n=?) did not experience graft loss or rejection.
- Non-responders showed minimal or no CD complex recovery and had a low rate of rejection.
Conclusions:
- CD complex activity following OKT3 cessation is predictive of renal allograft rejection.
- Individualized immunosuppression strategies can be tailored based on CD complex responder status.
- Monitoring immune cell recovery offers valuable insights into transplant rejection risk.